We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Adiponectin Linked to Cancer Risk in Diabetes

By LabMedica International staff writers
Posted on 17 Mar 2020
Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid oxidation. More...
Adiponectin is secreted from adipose tissue, and also from the placenta in pregnancy, into the bloodstream and is very abundant in plasma relative to many hormones.

Despite the beneficial cardiometabolic effects of adiponectin demonstrated in preclinical studies, paradoxically higher circulating adiponectin concentrations have been found in epidemiological studies to be associated with incident cardiovascular events, renal outcomes, and mortality in patients with diabetes.

Medical scientists at the University of Hong Kong (Pokfulam, Hong Kong, China) and their colleagues carried out a prospective cohort study, and analyzed data from 5,658 adults with type 2 diabetes recruited from the Hong Kong West Diabetes Registry (median follow-up, 6.5 years). The team measured baseline serum adiponectin concentrations and stratified participants according to adiponectin tertiles (< 7.23 µg/mL, 7.23-12 µg/mL, >12 µg/mL), and used Cox regression analysis to estimate associations between circulating adiponectin concentrations with incident cancer and cancer-related mortality.

The investigators reported that over a median-follow up of 6.5 years, 7.53% and 3% of participants developed cancer and had cancer-related deaths, respectively. Serum adiponectin concentrations were significantly higher in those who had incident cancer (9.8 μg/mL versus 9.1 μg/mL) and cancer-related deaths (11.5 μg/mL versus 9.3 μg/mL) compared with those without. Moreover, in multivariable analyses, serum adiponectin concentration was independently associated with both incident cancer (hazard ratio (HR) = 1.19) and cancer-related deaths (HR = 1.23). In sex-stratified analyses, the association between serum adiponectin and incident cancer was only observed among men (HR = 1.23).

The authors concluded that higher serum adiponectin concentration was independently associated with incident cancer and cancer-related deaths in type 2 diabetes, indicating that adiponectin paradox can be observed in another major diabetic complication in addition to cardiovascular and kidney diseases.

Karen Lam, MD, professor of medicine and the senior author of the study, said, “Although adiponectin, a hormone from the fat cells, has been reported to protect against cancers in animal studies, mostly in mice, higher levels of adiponectin paradoxically predicted the development of cancer and death due to cancers in this study of more than 5,000 people with diabetes”. The study was published online on February 19, 2020 in The Journal of Clinical Endocrinology & Metabolism.

Related Links:
University of Hong Kong


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.